ALN-SOD + Placebo (PB)

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Amyotrophic Lateral Sclerosis (ALS)

Conditions

Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Trial Timeline

Aug 28, 2024 → Jun 5, 2031

NCT ID

NCT06351592

About ALN-SOD + Placebo (PB)

ALN-SOD + Placebo (PB) is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Amyotrophic Lateral Sclerosis (ALS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06351592. Target conditions include Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene.

What happened to similar drugs?

2 of 18 similar drugs in Amyotrophic Lateral Sclerosis (ALS) were approved

Approved (2) Terminated (4) Active (12)

🔄methylcobalamin + saline solutionEisaiPhase 3

🔄Olesoxime + Placebo Comparator + RiluzoleRochePhase 3

✅RiluzoleSanofiApproved

🔄Tofersen + PlaceboBiogenPhase 3

❌DexpramipexoleBiogenPhase 3

✅TofersenBiogenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06351592	Phase 1/2	Recruiting	Aug 28, 2024	Jun 5, 2031	Amyotrophic Lateral Sclerosis (ALS)

Competing Products

20 competing products in Amyotrophic Lateral Sclerosis (ALS)

See all competitors

Product	Company	Stage	Hype Score
AL001 + Placebo	Alector	Phase 2	17
89Zr-DFO-AP-101	Eli Lilly	Phase 1	33
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	35
Perampanel + Placebo Oral Tablet	Eisai	Pre-clinical	18
E0302 (mecobalamin)	Eisai	Phase 2/3	38
E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo	Eisai	Phase 2/3	38
methylcobalamin + saline solution	Eisai	Phase 3	40
ONO-2506PO	Ono Pharmaceutical	Phase 2	35
ONO-2506PO + ONO-2506PO	Ono Pharmaceutical	Phase 2	35
ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg	Zydus Lifesciences	Phase 2	35
LY4256984 + Placebo	Eli Lilly	Phase 1	36
TCH346	Novartis	Phase 2	35
VHB937	Novartis	Phase 2	39
TCH346	Novartis	Phase 2	35
TCH346	Novartis	Phase 2	35
BLZ945	Novartis	Phase 2	27
TRO19622	Roche	Phase 2/3	38
Olesoxime + Placebo Comparator + Riluzole	Roche	Phase 3	40
Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)	Pfizer	Phase 1/2	28
Celecoxib + Creatine + Minocycline	Pfizer	Phase 2	35